Actinium Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Actinium Pharmaceuticals Inc (ATNM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Actinium Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 91,510M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+9,475.9% annualized vs trailing 12 months), vs accelerating (+2.0%) for its tracked peer group.
- Profitability: Its 159.4% net margin compares with 19.1% for the peer group.
- Scale: Actinium Pharmaceuticals Inc ranks #325 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Actinium Pharmaceuticals Inc accounted for 0.2% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.06M compares with $0.94M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ATNM Sales vs. its Competitors, Q2 2026
With a net margin of 159.43 %, Actinium Pharmaceuticals Inc achieved higher profitability than its competitors (19.10 %).
Actinium Pharmaceuticals Inc generated 0.15 % of the combined sales of its peer group.
API endpoints for this dataset
Actinium Pharmaceuticals Inc vs. its Competitors, Q2 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Actinium Pharmaceuticals Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Actinium Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Actinium Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Actinium Pharmaceuticals Inc's competitor groups requires a Commercial License.
Actinium Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Actinium Pharmaceuticals Inc | - | - | - | Yes |
| Competitors combined (139) | ||||
| High-Confidence Competitors (17) | ||||
| Similar-Size Competitors (10) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ATNM Stock Performance relative to its Competitors
ATNM Stock Performance relative to High-Confidence Competitors
ATNM Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Inmed Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 4 | Erasca Inc | 282.9% | Outperformed |
| 5 | Climb Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Actinium Pharmaceuticals Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Actinium Pharmaceuticals Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Actinium Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Actinium Pharmaceuticals Inc |
44.91 | 1.46 |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Astrazeneca Plc |
291,203.66 | 58,739.00 |
 Vertex Pharmaceuticals Inc |
139,617.37 | 12,951.60 |
 Bristol myers Squibb Company |
127,573.42 | 50,033.00 |
 Regeneron Pharmaceuticals Inc |
95,499.36 | 16,896.20 |
| SUBTOTAL | 1,150,948.12 | 208,860.47 |
Sign in to see all competitors of Actinium Pharmaceuticals Inc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Actinium Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Actinium Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Actinium Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Cellectar Biosciences | Company report | 85% |
| Molecular Partners | Company report | 85% |
| Bristol Myers Squibb | Company report | 85% |
| Novartis | Company report | 85% |
| Perspective Therapeutics | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Convergent Therapeutics | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Radiopharm Theranostics | Company report | 85% |
| AstraZeneca/Merck | Company report | 85% |
| Pfizer | Company report | 85% |
| Telix Pharmaceuticals | Company report | 85% |
| Astellas/Pfizer | Company report | 85% |
| Daiichi Sankyo | Company report | 85% |
| Ratio Therapeutics | Company report | 85% |
| AbbVie | Company report | 85% |
| Bayer | Company report | 85% |
| Clarity Pharmaceuticals | Company report | 85% |
| Plus Therapeutics | Company report | 85% |
| AstraZeneca | Company report | 85% |
| Lilly | Company report | 85% |
| Roche | Company report | 85% |
| Aktis Oncology | Company report | 85% |
| Bicycle Therapeutics | Company report | 85% |
| LG Chem | Company report | 85% |
| EpicentRx | Company report | 85% |
| NorthStar Medical Radioisotopes | Company report | 85% |
| TRIUMF | Company report | 85% |
| IONETIX Corporation | Company report | 85% |
| ITM | Company report | 85% |
| Niowave | Company report | 85% |
| Terrapower | Company report | 85% |
| Canadian Nuclear Laboratories | Company report | 85% |
| Jasper Therapeutics Inc | Company report | 85% |
| Q Biomed inc | Company report | 85% |
| Rayzebio Inc | Company report | 85% |
| Lantheus Holdings Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Actinium Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Actinium Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Actinium Pharmaceuticals Inc.
Actinium Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Actinium Pharmaceuticals Inc | 45 | 58,480 | 1,514,120 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Astrazeneca Plc | 291,204 | 706,847 | 123,141 |
| Vertex Pharmaceuticals Inc | 139,617 | 31,979,259 | 9,817,037 |
| Bristol myers Squibb Company | 127,573 | 1,539,477 | 284,338 |
| Regeneron Pharmaceuticals Inc | 95,499 | 1,096,444 | 312,615 |
| PEERS TOTAL | 1,150,903 | 937,277 | 164,557 |
Sign in to see all peers for Actinium Pharmaceuticals Inc.
Actinium Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Bristol myers Squibb Company | United States 69.43 % |
| United Therapeutics Corporation | UNITED STATES 97.12 % |
| Hutchmed china Limited | CN 74.28 % |
| Lantheus Holdings Inc | US 94.03 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Actinium Pharmaceuticals Inc.
Actinium Pharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Actinium Pharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Actinium Pharmaceuticals Inc ranks #325 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 325 | Actinium Pharmaceuticals Inc | 45 | 0.00 % |
Market cap and industry share for the rest of Actinium Pharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Actinium Pharmaceuticals Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 320 | Oncolytics Biotech Inc | 51 | -55.56 % |
| 321 | Pliant Therapeutics Inc | 50 | -50.62 % |
| 322 | Werewolf Therapeutics Inc | 49 | -15.57 % |
| 323 | Clene Inc | 49 | -63.03 % |
| 324 | Veru Inc | 1,234 | 12.3% |
| 325 | Actinium Pharmaceuticals Inc | 45 | 0.75 % |
| 326 | Gain Therapeutics inc | 1,234 | 12.3% |
| 327 | Os Therapies Incorporated | 1,234 | 12.3% |
| 328 | Dogwood Therapeutics inc | 1,234 | 12.3% |
| 329 | Connect Biopharma Holdings Limited | 1,234 | 12.3% |
| 330 | Telomir Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Actinium Pharmaceuticals Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Actinium Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 3.6x | 26.6x | -23.0x |
| EV / EBITDA | - | 15.9x | - |
| P/B | 2.0x | 4.3x | -2.2x |
| Return on Equity | 213.46 % | industry aggregate | 197.11 % |
| Return on Invested Capital | 12.71 % | -9.82 % (avg) | 22.53 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Actinium Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | -2,182.17 % | - | - | - | - |
| Return on Invested Capital | -80.14 % | -115.03 % | -27.73 % | -16.36 % | -23.62 % | -45.45 % | -32.44 % | -30.77 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Actinium Pharmaceuticals Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Actinium Pharmaceuticals Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Actinium Pharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Actinium Pharmaceuticals Inc's dedicated Suppliers and Customers pages, not here.
Actinium Pharmaceuticals Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Actinium Pharmaceuticals Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Actinium Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 197.1 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+9,475.9% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Trades at a lower P/E than the industry average (3.6x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (57.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Actinium Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Actinium Pharmaceuticals Inc | 6.11 | 6.25 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
Sign in to see all peers for Actinium Pharmaceuticals Inc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Actinium Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Actinium Pharmaceuticals Inc | Q2 2026 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| PEERS TOTAL | +10.3 % | +37.0 % |
Sign in to see all peers for Actinium Pharmaceuticals Inc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Actinium Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Actinium Pharmaceuticals Inc | Q2 2026 | - | - |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
Sign in to see all peers for Actinium Pharmaceuticals Inc.
Actinium Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Actinium Pharmaceuticals Inc | 71.73% | 84.38% | 213.46% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
Sign in to see all peers for Actinium Pharmaceuticals Inc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Actinium Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Actinium Pharmaceuticals Inc | 4.47 | 30.72 |
| Novartis Ag | 22.73 | 5.61 |
| Astrazeneca Plc | 28.51 | 4.96 |
| Vertex Pharmaceuticals Inc | 35.27 | 10.78 |
| Bristol myers Squibb Company | 13.77 | 2.55 |
| Regeneron Pharmaceuticals Inc | 20.00 | 5.65 |
| PEERS AVERAGE | 31.35 | 5.51 |
Sign in to see all peers for Actinium Pharmaceuticals Inc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.